Research

The Parker Lab seeks to understand the mechanisms that underlie neuro-dysfunctions such as epilepsy, and develop early targeted therapies to disrupt these mechanisms.

Uncovering STRADA’s role in neuronal migration and epilepsy

We are particularly interested in a disease called Polyhydramnios, Megalencephaly, and Symptomatic Epilepsy syndrome (PMSE, colloquially referred to as Pretzel Syndrome), which results from a loss-of-function mutation in the STRADA gene. This disease has a prevalence in the Old Order Mennonite population, with a carrier frequency of around 4%, and STRADA is a megalencephaly-associated gene in the general population. PMSE causes severe, medically refractory infantile-onset seizures, and is associated with significant neurocognitive dysfunction and a high rate of prenatal, infantile, and childhood death. We are investigating mechanisms of how different types of neurons migrate during early brain development, to uncover therapeutic strategies that would allow us to offer early targeted treatment for this devastating disease. We work with PMSE families and clinicians at the Clinic for Special Children in Lancaster County, PA to advance our understanding from their experiences and update them on our findings.

Low-intensity FUS to interrupt epileptic network development

In another project, we are investigating the utility of low-intensity focused ultrasound (FUS) to disrupt the formation of epileptic networks in a rat kainic acid model of mesial temporal epilepsy, with implications for other forms of epilepsy. We are targeting the hippocampus during a critical latent period after initial “injury” to alter cellular ion flux and promote inhibitory GABAergic rather than excitatory glutamatergic activity and network connections, to dampen network hyperactivity that otherwise results in spontaneous seizures.

Fetal gene delivery to treat neurodevelopmental disorders

In a third project, we are innovating safe methods of fetal gene delivery, with the goal of targeting monogenic disorders. As early diagnosis of severe neurodevelopmental disorders has become feasible, so too should therapies which have the potential to prevent development of aberrant neural networks. More to come on this!

Techniques